C4 Therapeutics (CCCC)
Develops targeted-protein degraders for oncology through TORPEDO.
Something off on this page? Send us feedback.
13F · 13D/G · Form 4
| Institutions | ≈ 106.62% | 117.89M shares | |
|---|---|---|---|
| 158 holders · as of Jun 30, 2026 · largest filers plus last quarter's tail | |||
| Insiders | 2.80% | 3.09M shares | |
| 10 holders · as of Sep 21, 2026 | |||
| Adds to | 109.42% | ||
110.57M company shares as of Aug 26, 2026 · institutions as of Jun 30, 2026 · holders as of their latest filing
Two share counts disagree (123.03M in the company's Sep 22, 2026 report, 110.57M elsewhere); stakes use the report.
This quarter's institutional total failed a plausibility check; shown: the largest filers plus last quarter's remainder.
These groups come from separate filings that can overlap, so they add to 109.42%; nothing is left for Other.
13F, as of Jun 30, 2026
158 holders · 117.89M shares · 54 new positions · 107 increased · 28 reduced · 26 closed
| Holder | Shares | % outstanding | Chg q/q | Filed |
|---|---|---|---|---|
| Morgan Stanley | 8.87M | 8.02% | −205.1K | Aug 13, 2026 |
| Ra Capital Management, L.P. | 8.00M | 7.24% | 0 | Aug 14, 2026 |
| BlackRock, Inc. | 7.90M | 7.14% | +5.85M | Aug 7, 2026 |
| LYNX1 Capital Management LP | 7.33M | 6.63% | +327.8K | Aug 13, 2026 |
| Squadron Capital Management LLC | 7.20M | 6.51% | +4.95M | Aug 14, 2026 |
| Bain Capital Life Sciences Investors, LLC | 7.17M | 6.49% | 0 | Aug 14, 2026 |
| JPMorgan Chase & Co | 4.75M | 4.29% | +1.52M | Aug 12, 2026 |
| Vanguard Capital Management LLC | 4.42M | 4.00% | +555.9K | Aug 13, 2026 |
13D/G · 5% or more, as filed
| Holder | % of class | Shares | Form | Filed |
|---|---|---|---|---|
| Sirenia Capital Management LP | 9.90% | 23.51M | 13G | May 15, 2026 |
| RA Capital Management, L.P. | 9.90% | 9.44M | 13G | Oct 24, 2025 |
| Morgan Stanley | 9.30% | 8.97M | 13G | Feb 11, 2026 |
| Lynx1 Capital Management LP | 7.30% | 7.10M | 13G | Feb 17, 2026 |
| BlackRock, Inc. | 6.90% | 7.68M | 13G | Jul 27, 2026 |
| Soleus Private Equity Fund III, L.P. | 5.90% | 6.07M | 13G | Feb 12, 2026 |
| Squadron Master Fund LP | 5.00% | 5.55M | 13G | May 19, 2026 |
Form 4
Latest trades
| Date | Insider | Type | Shares | Avg price | Owned after |
|---|---|---|---|---|---|
| Jan 16, 2026 | Leonard Reynoofficer: Chief Medical Officer | Sale | 10,000 | $2.22 | 156,382 |
House and Senate disclosures
Not reported.